Table 3.
Comparison of the postoperative outcomes of 413 patients treated with retroperitoneal minimally invasive partial nephrectomy with selected matched 413 patients treated with transperitoneal minimally invasive partial nephrectomy for renal tumors within the RECORD 2 project
| RECORD 2 project—report of early postoperative and functional follow-up outcomes | Surgical access | p value | |
|---|---|---|---|
| Transpertioneal (n = 413) | Retroperitoneal (n = 413) | ||
| Surgical postoperative complications, n (%) | 29 (7%) | 25 (6.1%) | 0.57 |
| Surgical clavien 2 postop complications, n (%) | 12 (2.9%) | 11 (2.7%) | |
| Surgical clavien 3a, postop complications, n (%) | 11 (2.7%) | 10 (2.4%) | |
| Surgical clavien 3b, postop complications, n (%) | 3 (0.7%) | 4 (1%) | |
| Surgical clavien 4a, postop complications, n (%) | 3 (0.7%) | 0 | |
| Transfusions, n (%) | 21 (5.1%) | 15 (3.6%) | |
| Deep vein thrombosis, n (%) | 1 (0.2%) | 0 | |
| Superselective embolization, n (%) | 8 (2.0%) | 7 (1.7%) | |
| Urinary fistula treated without stenting, n (%) | 4 (0.8%) | 4 (0.8%) | |
| Urinary fistula treated with stenting or nephrostomy tube, n (%) | 2 (0.4%) | 1 (0.2%) | |
| Medical postoperative complications, n (%) | 16 (3.9%) | 14 (3.4%) | 0.48 |
| Respiratory complications, n (%) | 8 (2.0%) | 8 (2.0%) | |
| Cardiologic complications, n (%) | 7 (1.7%) | 5 (1.2%) | |
| Acute pulmonary embolism, n (%) | 1 (0.2%) | 1 (0.2%) | |
| Drainage duration (days), median (IQR) | 3 (2–4) | 2 (1–2) | < 0.0001 |
| Time to bowel canalization, median (IQR) | 3 (2–5) | 2 (1–3) | < 0.0001 |
| Hospital length of stay (days), median (IQR) | 3 (3–4) | 2 (2–3) | < 0.0001 |
| Malignant tumors, n (%) | 308 (74.6%) | 310 (75.1%) | 0.82 |
| Positive surgical margins, n (%) | 21 (5.1%) | 23 (5.6%) | 0.73 |
| Preoperative—1st postoperative day Δ hemoglobin (mg/dL), median (IQR) | 1.7 (1.1–3.0) | 1.5 (0.9–2.7) | 0.48 |
| Preoperative—3rd postoperative day Δ hemoglobin (mg/dL), median (IQR) | 2.2 (1.4–3.1) | 1.8 (1.0–2.9) | 0.25 |
| 1st POD creatinine (mg/dl), median (IQR) | 1.0 (0.8–1.2) | 1.0 (0.8–1.3) | 0.18 |
| 1st POD eGFR, median (IQR) | 76 (61.0–89.0) | 73 (57.2–89.0) | 0.08 |
| Preoperative—1st POD Δ eGFR, median (IQR) | 10.3 (0.0–20.8) | 10.4 (0.0–22.5) | 0.69 |
| Preoperative—3rd POD Δ eGFR, median (IQR) | 10.1 (0.0–20.1) | 9.0 (0.0–20.7) | 0.53 |
| Preoperative—6th month Δ eGFR, median (IQR) | 8.7 (0.3–15.9) | 8.8 (0.4–15.0) | 0.65 |
| Preoperative—12th month Δ eGFR, median (IQR) | 9.2 (4.1–21.5) | 9.3 (3.4–20.8) | 0.67 |
| Preoperative—24th month Δ eGFR, median (IQR) | 9.6 (4.4–20.5) | 9.8 (4.5–20.0) | 0.68 |